Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Circulation. 2005;112:2307-2317
doi: 10.1161/CIRCULATIONAHA.105.542209
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kilic, A.
Right arrow Articles by Kuhn, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kilic, A.
Right arrow Articles by Kuhn, M.
Right arrowPubmed/NCBI databases
*Gene*GEO Profiles
*HomoloGene*UniGene
*Substance via MeSH
Related Collections
Right arrow Cardio-renal physiology/pathophysiology
Right arrow Cardiovascular Pharmacology
Right arrow Animal models of human disease
Right arrow Other hypertension
Right arrow Hypertrophy

(Circulation. 2005;112:2307-2317.)
© 2005 American Heart Association, Inc.


Hypertension

Enhanced Activity of the Myocardial Na+/H+ Exchanger NHE-1 Contributes to Cardiac Remodeling in Atrial Natriuretic Peptide Receptor–Deficient Mice

Ana Kilic, PhD; Ana Velic, PhD; León J. De Windt, PhD; Larissa Fabritz, MD; Melanie Voss; Danuta Mitko; Melanie Zwiener, DVM; Hideo A. Baba, MD; Martin van Eickels, MD; Eberhard Schlatter, PhD; Michaela Kuhn, MD

From the Institute of Physiology, University of Würzburg (A.K., M.K.), Würzburg, Germany; the Institute of Pharmacology and Toxicology (A.K., M.V., D.M., M.K.), the Department of Internal Medicine D, Experimental Nephrology (A.V., E.S.), the Department of Cardiology and Angiology (L.F., M.Z.), and Interdisciplinary Center for Clinical Research, University of Münster (A.K., A.V., L.F., M.Z., E.S., M.K.), Münster, Germany; the Institute of Pathology, University of Duisburg-Essen (H.A.B.), Duisburg-Essen, Germany; TD Cardiovascular Diseases, Sanofi-Aventis (M.v.E.), Frankfurt, Germany; and Hubrecht Laboratory and Interuniversity Cardiology Institute Netherlands, Royal Netherlands Academy of Sciences, Utrecht (L.J.D.W.), The Netherlands.

Correspondence to Michaela Kuhn, Physiologisches Institut der Universität Würzburg, Röntgenring 9, D - 97070 Würzburg, Germany. E-mail michaela.kuhn{at}mail.uni-wuerzburg.de

Received February 10, 2005; revision received July 14, 2005; accepted July 19, 2005.

Background— Atrial natriuretic peptide (ANP), through its guanylyl cyclase-A (GC-A) receptor, not only is critically involved in the endocrine regulation of arterial blood pressure but also locally moderates cardiomyocyte growth. The mechanisms underlying the antihypertrophic effects of ANP remain largely uncharacterized. We examined the contribution of the Na+/H+ exchanger NHE-1 to cardiac remodeling in GC-A–deficient (GC-A–/–) mice.

Methods and Results— Fluorometric measurements in isolated adult cardiomyocytes demonstrated that cardiac hypertrophy in GC-A–/– mice was associated with enhanced NHE-1 activity, alkalinization of intracellular pH, and increased Ca2+ levels. Chronic treatment of GC-A–/– mice with the NHE-1 inhibitor cariporide normalized cardiomyocyte pH and Ca2+ levels and regressed cardiac hypertrophy and fibrosis, despite persistent arterial hypertension. To characterize the molecular pathways driving cardiac hypertrophy in GC-A–/– mice, we evaluated the activity of 4 prohypertrophic signaling pathways: the mitogen-activated protein kinases (MAPK), the serine-threonine kinase Akt, calcineurin, and Ca2+/calmodulin-dependent kinase II (CaMKII). The results demonstrate that all 4 pathways were activated in GC-A–/– mice, but only CaMKII and Akt activity regressed during reversal of the hypertrophic phenotype by cariporide treatment. In contrast, the MAPK and calcineurin/NFAT signaling pathways remained activated during regression of hypertrophy.

Conclusions— On the basis of these results, we conclude that the ANP/GC-A system moderates the cardiac growth response to pressure overload by preventing excessive activation of NHE-1 and subsequent increases in cardiomyocyte intracellular pH, Ca2+, and CaMKII as well as Akt activity.


Key Words: hypertension • natriuretic peptides • hypertrophy • calcineurin • sodium-hydrogen antiporter




This article has been cited by other articles:


Home page
CirculationHome page
T. Tokudome, I. Kishimoto, T. Horio, Y. Arai, D. O. Schwenke, J. Hino, I. Okano, Y. Kawano, M. Kohno, M. Miyazato, et al.
Regulator of G-Protein Signaling Subtype 4 Mediates Antihypertrophic Effect of Locally Secreted Natriuretic Peptides in the Heart
Circulation, May 6, 2008; 117(18): 2329 - 2339.
[Abstract] [Full Text] [PDF]


Home page
EndocrinologyHome page
A. Kilic, A. Bubikat, B. Gassner, H. A. Baba, and M. Kuhn
Local Actions of Atrial Natriuretic Peptide Counteract Angiotensin II Stimulated Cardiac Remodeling
Endocrinology, September 1, 2007; 148(9): 4162 - 4169.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
H. E. Cingolani and I. L. Ennis
Sodium-Hydrogen Exchanger, Cardiac Overload, and Myocardial Hypertrophy
Circulation, March 6, 2007; 115(9): 1090 - 1100.
[Full Text] [PDF]


Home page
Cardiovasc ResHome page
S. Yurukova, A. Kilic, K. Volker, K. Leineweber, N. Dybkova, L. S. Maier, O.-E. Brodde, and M. Kuhn
CaMKII-mediated increased lusitropic responses to {beta}-adrenoreceptor stimulation in ANP-receptor deficient mice
Cardiovasc Res, March 1, 2007; 73(4): 678 - 688.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
D. G. Gardner, S. Chen, D. J. Glenn, and C. L. Grigsby
Molecular Biology of the Natriuretic Peptide System: Implications for Physiology and Hypertension
Hypertension, March 1, 2007; 49(3): 419 - 426.
[Full Text] [PDF]


Home page
J. Physiol.Home page
B. V. Alvarez, D. E. Johnson, D. Sowah, D. Soliman, P. E. Light, Y. Xia, M. Karmazyn, and J. R. Casey
Carbonic anhydrase inhibition prevents and reverts cardiomyocyte hypertrophy
J. Physiol., February 15, 2007; 579(1): 127 - 145.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
T.-M. Lee, M.-S. Lin, C.-H. Tsai, and N.-C. Chang
Effect of pravastatin on left ventricular mass in the two-kidney, one-clip hypertensive rats
Am J Physiol Heart Circ Physiol, December 1, 2006; 291(6): H2705 - H2713.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
S. Javadov, D. M. Purdham, A. Zeidan, and M. Karmazyn
NHE-1 inhibition improves cardiac mitochondrial function through regulation of mitochondrial biogenesis during postinfarction remodeling
Am J Physiol Heart Circ Physiol, October 1, 2006; 291(4): H1722 - H1730.
[Abstract] [Full Text] [PDF]


Home page
FASEB J.Home page
A. Kilic, S. Yurukova, D. Mitko, L. Fabritz, and M. Kuhn
Calcium-calmoduline kinase II plays a important role in cardiac hypertrophy in ANP receptor deficient mice
FASEB J, March 1, 2006; 20(4): A311 - A311.
[Abstract] [Full Text]